HCC Stock Recent News

Warrior Met Coal boasts strong margins, low transport costs, and a robust balance sheet, outperforming peers despite weak coking coal prices. Q2 2025 results beat expectations with higher EBITDA and improved cash margins, aided by cost reductions and increased sales guidance. Blue Creek project is ahead of schedule, set to boost production and EBITDA by 50-60%, supporting future growth.

Warrior Met Coal, Inc. (NYSE:HCC ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Brian M. Chopin - Senior VP, Chief Accounting Officer & Controller Dale W.

Warrior Met Coal (HCC) Q2 EPS Beats View

Warrior Met Coal (HCC) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of a loss of $0.28 per share. This compares to earnings of $1.35 per share a year ago.

Warrior Met Coal (HCC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BROOKWOOD, Ala.--(BUSINESS WIRE)--Warrior Met Coal, Inc. (NYSE:HCC) (“Warrior” or the “Company”) today announced that its board of directors has approved a regular quarterly cash dividend of $0.08 per share to be paid on August 15, 2025, to stockholders of record as of the close of business on August 8, 2025. About Warrior Warrior is a U.S.-based, environmentally, and socially minded supplier to the global steel industry. It is dedicated entirely to mining non-thermal metallurgical (met) coal u.

BROOKWOOD, Ala.--(BUSINESS WIRE)--Warrior Met Coal, Inc. (“Warrior” or NYSE: HCC) today announced that it will hold its second quarter 2025 investor conference call at 4:30 p.m. ET on Wednesday, August 6, 2025. Warrior will release its results following the close of market trading that afternoon. To participate in the conference call, please call 1-844-340-9047 (domestic) or 1-412-858-5206 (international) 10 minutes prior to the start time and reference the Warrior Met Coal conference call. A w.

Warrior Met Coal is slightly more attractive than Alpha Metallurgical Resources due to higher gross margins and average coal quality, but both remain fundamentally sound. Until metallurgical coal prices bottom and trade policy uncertainties dissipate, a Hold rating for both HCC and AMR seems justified. While valuations for both companies are historically high, HCC is currently relatively cheaper than AMR.

BRISBANE, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that the company received approval from the National Medical Products Administration (NMPA) in China to proceed with a pivotal trial to evaluate amezalpat (TPST-1120) in combination with atezolizumab and bevacizumab, the current standard of care, versus the standard of care alone in the first-line treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC).

EMA Orphan Drug Designation (ODD) builds on U.S. Food & Drug Administration (FDA) ODD and Fast Track Designation, underscoring the urgent need for new treatment options The multiple regulatory designations were granted following strong positive results from a global randomized Phase 1b/2 study in first-line HCC demonstrating superior outcomes for amezalpat combination therapy across multiple study endpoints, including overall survival in both the entire population and key subpopulations, when compared to standard of care alone BRISBANE, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to amezalpat (TPST-1120), an oral, small molecule, selective PPAR⍺ antagonist for the treatment of patients with hepatocellular carcinoma